In 2016, the world’s first cancer diagnostic product based on exosome miRNAs body fluid biopsy, ExoDx Lung (ALK), was launched, which could detect EML4-ALK mutations in patients with non-small cell lung cancer in real time [113]. This evidence concerns the gene ALK and non-small cell lung carcinoma.